Calamos Advisors LLC lowered its stake in shares of Steris Corp. (NYSE:STE) by 52.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 49,325 shares of the company’s stock after selling 54,291 shares during the period. Calamos Advisors LLC’s holdings in Steris Corp. were worth $3,391,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in the stock. American Century Companies Inc. increased its stake in Steris Corp. by 870.8% in the second quarter. American Century Companies Inc. now owns 1,208,491 shares of the company’s stock valued at $83,084,000 after buying an additional 1,084,007 shares in the last quarter. Villere ST Denis J & Co. LLC bought a new stake in Steris Corp. during the second quarter valued at about $46,505,000. Bank of Montreal Can bought a new stake in Steris Corp. during the second quarter valued at about $22,429,000. Royal Bank of Canada increased its stake in Steris Corp. by 109.5% in the first quarter. Royal Bank of Canada now owns 468,134 shares of the company’s stock valued at $33,261,000 after buying an additional 244,710 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Steris Corp. by 43.9% in the first quarter. JPMorgan Chase & Co. now owns 616,502 shares of the company’s stock valued at $43,802,000 after buying an additional 187,935 shares in the last quarter. 91.58% of the stock is owned by institutional investors and hedge funds.
Shares of Steris Corp. (NYSE:STE) traded up 0.65% during midday trading on Friday, hitting $73.10. The company had a trading volume of 622,047 shares. Steris Corp. has a 1-year low of $61.38 and a 1-year high of $78.77. The firm has a market capitalization of $6.30 billion, a P/E ratio of 41.99 and a beta of 1.16. The stock has a 50 day moving average price of $71.34 and a 200 day moving average price of $70.24.
Steris Corp. (NYSE:STE) last posted its earnings results on Tuesday, August 9th. The company reported $0.79 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.02. Steris Corp. had a net margin of 5.52% and a return on equity of 10.72%. The business earned $638.40 million during the quarter, compared to the consensus estimate of $639.04 million. During the same quarter in the previous year, the firm posted $0.62 EPS. The firm’s revenue was up 45.1% on a year-over-year basis. On average, equities analysts anticipate that Steris Corp. will post $3.90 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 27th. Stockholders of record on Tuesday, August 30th were given a dividend of $0.28 per share. This is an increase from Steris Corp.’s previous quarterly dividend of $0.25. The ex-dividend date of this dividend was Friday, August 26th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.53%. Steris Corp.’s payout ratio is presently 68.71%.
Separately, Zacks Investment Research upgraded Steris Corp. from a “sell” rating to a “hold” rating in a research report on Friday, September 2nd.
In other news, CEO Walter M. Rosebrough, Jr. sold 15,000 shares of the business’s stock in a transaction on Wednesday, August 17th. The shares were sold at an average price of $71.08, for a total transaction of $1,066,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Sudhir K. Pahwa sold 1,028 shares of the business’s stock in a transaction on Friday, August 26th. The shares were sold at an average price of $70.13, for a total transaction of $72,093.64. The disclosure for this sale can be found here. Insiders own 2.52% of the company’s stock.
Steris Corp. Company Profile
STERIS Corporation (STERIS) is a provider of infection prevention and other procedural products and services. The Company is focused on healthcare, pharmaceutical and research. The Company operates through three business segments: Healthcare, Life Sciences and STERIS Isomedix Services. The Healthcare segment provides surgical, sterile processing, infection prevention and gastrointestinal solutions.
Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Steris Corp. (NYSE:STE).
Receive News & Ratings for Steris Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris Corp. and related companies with MarketBeat.com's FREE daily email newsletter.